Sugi Predict

Sugi Predict / Targets / EGLN3

EGLN3

Prolyl hydroxylase EGLN3 · Q9H6Z9 · EGLN3 on Sugi Atlas →

21,971 patent compounds predicted against EGLN3, 15,745 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL336908 SCHEMBL336908 0.55 7/20
SCHEMBL338012 SCHEMBL338012 0.59 6/20
SCHEMBL303114 SCHEMBL303114 0.59 6/20
SCHEMBL337817 SCHEMBL337817 0.58 6/20
SCHEMBL303191 SCHEMBL303191 0.51 6/20
SCHEMBL523136 SCHEMBL523136 0.61 3/20
SCHEMBL522880 SCHEMBL522880 0.55 3/20
SCHEMBL521828 SCHEMBL521828 0.53 3/20
SCHEMBL522241 SCHEMBL522241 0.52 3/20
SCHEMBL523283 SCHEMBL523283 0.49 3/20
SCHEMBL418948 SCHEMBL418948 0.45 3/20
SCHEMBL565272 SCHEMBL565272 0.92 2/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL564853) 0.90 2/20
SCHEMBL418916 SCHEMBL418916 0.72 2/20
SCHEMBL283896 SCHEMBL283896 0.60 2/20
SCHEMBL437788 SCHEMBL437788 0.59 2/20
SCHEMBL423151 SCHEMBL423151 0.58 2/20
SCHEMBL420173 SCHEMBL420173 0.56 2/20
SCHEMBL102142 SCHEMBL102142 0.55 2/20
SCHEMBL324038 SCHEMBL324038 0.54 2/20

Clinical trials — most relevant to EGLN3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia PHASE2COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Study of the Effects of Iron on Lung Blood Pressure at High Altitude PHASE2WITHDRAWN
Value of Using Pioglitazone in Chronic Myeloid Leukemia Treatment PHASE2COMPLETED
Carnosine for Peripheral Vascular Disease PHASE2UNKNOWN
Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients PHASE2COMPLETED
MBM-02 (Tempol) for the Treatment of Glioblastoma Multiforme (GBM) PHASE2UNKNOWN
Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients PHASE1/PHASE2RECRUITING
Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment PHASE1COMPLETED
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing PHASE1WITHDRAWN
Repeat Dose Safety Study for Compound to Treat Anemia PHASE1COMPLETED
A Pilot Study of EZN-2968, an Antisense Oligonucleotide Inhibitor of HIF-1alpha, in Adults With Advanced Solid Tumors With Liver Metastases PHASE1COMPLETED
Remote Ischemic Postconditioning Increases HIF-1α Plasma Levels and Improves Cardiac Markers After Cardiac Surgery nanCOMPLETED
Mitochondrial Function of Immune Cells in Sepsis nanCOMPLETED
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis nanUNKNOWN
Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock nanCOMPLETED
Selecting Hypoxic Tumours for Treatment Modification nanRECRUITING
Study of the Effects of Iron Levels on the Lungs at High Altitude nanCOMPLETED
Drivers of Hypoxia-induced Angiogenesis in Tumor Development nanUNKNOWN
Genes-in-Action - Hepcidin Regulation of Iron Supplementation nanCOMPLETED
Role of HIF-1α in Skeletal Muscle Aging nanUNKNOWN
Hypoxia Inducible factor1-Alpha Genetic Polymorphism of Obstructive Sleep Apnea nanUNKNOWN
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions nanRECRUITING
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a EGLN3 binder may also engage these)

ProteinNameSimilarity
Q91UZ4 — 0.997 Q91UZ4 →
Q01F03 — 0.981 Q01F03 →
Q2KHP8 — 0.978 Q2KHP8 →
A3KGZ2 — 0.977 A3KGZ2 →
A0A7T8F1L3 — 0.976 A0A7T8F1L3 →
P06593 — 0.975 P06593 →
Q7XR46 — 0.975 Q7XR46 →
Q9I7H9 — 0.975 Q9I7H9 →
Q582G4 — 0.974 Q582G4 →
A2WYE9 — 0.974 A2WYE9 →
G8XHD5 — 0.974 G8XHD5 →
Q67XC9 — 0.974 Q67XC9 →
Q9EQW7 — 0.974 Q9EQW7 →
P50264 — 0.974 P50264 →
O23461 — 0.974 O23461 →
Q12756 — 0.974 Q12756 →
Q7TMI3 — 0.974 Q7TMI3 →
Q95LP3 — 0.974 Q95LP3 →
Q2QRX6 — 0.974 Q2QRX6 →
F4IM84 — 0.973 F4IM84 →
F4IF36 — 0.973 F4IF36 →
Q08C92 — 0.973 Q08C92 →
P23337 — 0.973 P23337 →
O94536 — 0.973 O94536 →
Q4Q089 — 0.973 Q4Q089 →
Q9URV1 — 0.973 Q9URV1 →
A2XL32 — 0.973 A2XL32 →
P06592 — 0.973 P06592 →
P08413 — 0.973 P08413 →
B1JIH5 — 0.973 B1JIH5 →